News stories about Inogen (NASDAQ:INGN) have been trending somewhat positive this week, Accern Sentiment reports. The research group rates the sentiment of media coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Inogen earned a news impact score of 0.19 on Accern’s scale. Accern also gave news headlines about the medical technology company an impact score of 45.3162027555124 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
These are some of the news headlines that may have effected Accern Sentiment’s scoring:
- Insider Selling: Inogen Inc (INGN) EVP Sells 15,000 Shares of Stock (americanbankingnews.com)
- Insider Selling: Inogen Inc (INGN) CFO Sells 9,737 Shares of Stock (americanbankingnews.com)
- Inogen (INGN) Gains on Diverse Product Line, Competition Rife (finance.yahoo.com)
- Inogen (INGN) Downgraded by Zacks Investment Research to Hold (americanbankingnews.com)
- Insider Selling: Inogen Inc (INGN) EVP Sells 27,630 Shares of Stock (americanbankingnews.com)
A number of equities research analysts have recently weighed in on INGN shares. BidaskClub downgraded shares of Inogen from a “hold” rating to a “sell” rating in a research note on Saturday, January 6th. Needham & Company LLC raised their price target on shares of Inogen from $108.00 to $125.00 and gave the company a “strong-buy” rating in a research note on Wednesday, November 8th. Zacks Investment Research upgraded shares of Inogen from a “hold” rating to a “buy” rating and set a $131.00 price target on the stock in a research note on Thursday, November 9th. Finally, Leerink Swann restated an “outperform” rating and issued a $120.00 price target (up from $115.00) on shares of Inogen in a research note on Wednesday, November 8th. Three equities research analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the stock. Inogen presently has an average rating of “Buy” and an average target price of $103.71.
In other news, EVP Alison Bauerlein sold 27,630 shares of the firm’s stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $116.46, for a total value of $3,217,789.80. Following the sale, the executive vice president now directly owns 11,718 shares in the company, valued at approximately $1,364,678.28. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Scott Wilkinson sold 30,651 shares of Inogen stock in a transaction that occurred on Tuesday, January 16th. The stock was sold at an average price of $115.75, for a total transaction of $3,547,853.25. Following the sale, the insider now owns 38,107 shares in the company, valued at $4,410,885.25. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 140,236 shares of company stock worth $16,438,170. 5.31% of the stock is currently owned by corporate insiders.
Inogen Company Profile
Inogen, Inc is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device.
Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.